Settling In To The “New Normal”: Midway Through 2012, Another Banner Year For Drug Approvals Is Within Reach
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The forecast for 2012 approvals looks sunny. FDA approved almost as many novel drugs in the first half of 2012 as it did in the first half of its record-breaking 2011 – and the agency has more than twice as many pending NME applications with user fee goals in the next six months as it had last year.
You may also be interested in...
Encore? FDA Could Come Close To Record 2012 NME Count This Year
With 19 novel agents approved so far in 2013 and a full slate of candidates under review, the recovery in novel agent approvals after the doldrums of the 2000s is likely to continue even if the agency falls short of last year’s 45 approvals. Watch for action on the first “breakthrough” therapies submitted and advances in hepatitis C treatment.
Encore? FDA Could Come Close To Record 2012 NME Count This Year
With 19 novel agents approved so far in 2013 and a full slate of candidates under review, the recovery in novel agent approvals after the doldrums of the 2000s is likely to continue even if the agency falls short of last year’s 45 approvals. Watch for action on the first “breakthrough” therapies submitted and advances in hepatitis C treatment.
FDA Sees Another Submission Decrease In FY 2011, Increases Application Fees
The figures continue a recent trend of decreases in fee-paying full application equivalents but were not as low as had been estimated.